By: Daniel Trecroci
Richard K. Bernstein fears that Regular insulin will be the next to vanish from the American market.
“Sooner or later, they are going to discontinue Regular because of all the promotion given to the new analogues,” says Bernstein.
Bernstein prefers Regular to Humalog, because he feels it is more predictable and matches meal plans better for people who are following a lower-carbohydrate eating plan.
“But you have to wait 45 minutes for it to start working, which for some people is an inconvenience,” says Bernstein. “The greatest value I see in Humalog is for when you are eating out and you don’t know when you are going to be served, or if you are correcting a high BG and you want it to come down fast.”
When asked if Regular would be the next insulin to be pulled from the market, Novo Nordisk told Diabetes Health it does not comment on strategies or marketing practices for any of its products.
Eli Lilly told Diabetes Health that it regularly reviews its product portfolio and makes decisions based on patient demand, new innovations and market conditions. “However, we have no plans to discontinue Humulin R or Humulin NPH at this time.”